Sensei Biotherapeutics Files 8-K for Bylaw Amendments
Ticker: SNSE · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
TL;DR
Sensei Biotherapeutics filed an 8-K for bylaw changes and financials.
AI Summary
Sensei Biotherapeutics, Inc. filed an 8-K on June 13, 2025, reporting events as of June 12, 2025. The filing primarily concerns amendments to its articles of incorporation or bylaws and the submission of financial statements and exhibits. No specific financial figures or significant business changes were detailed in the provided excerpt.
Why It Matters
This filing indicates potential internal governance changes or the formal submission of required financial documents, which are standard corporate actions.
Risk Assessment
Risk Level: low — The filing appears to be routine corporate housekeeping and does not disclose any immediate material adverse events or significant financial shifts.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- June 12, 2025 (date) — Date of earliest event reported
- June 13, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What specific amendments were made to Sensei Biotherapeutics' articles of incorporation or bylaws?
The provided excerpt does not detail the specific amendments made to the articles of incorporation or bylaws; it only states that such amendments are reported.
What financial statements and exhibits are included in this 8-K filing?
The excerpt indicates that financial statements and exhibits are included, but it does not list their specific contents.
What is the primary purpose of this 8-K filing for Sensei Biotherapeutics?
The primary purpose is to report amendments to its articles of incorporation or bylaws and to file financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 12, 2025.
What is Sensei Biotherapeutics' principal executive office address?
Sensei Biotherapeutics' principal executive office is located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Sensei Biotherapeutics, Inc. (SNSE).